Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study
Authors:
- Annegien BroeksABAnnegien Broeks
- Linde M BraafLBLinde M Braaf
- Angelina HuseinovicAHAngelina Huseinovic
- Anke NooijenANAnke Nooijen
- Jos UrbanusJUJos Urbanus
- Frans Bl HogervorstFHFrans Bl Hogervorst
- Marjanka K SchmidtMarjanka K Schmidt
- Jan Gm KlijnJKJan Gm Klijn
- Nicola S RussellNRNicola S Russell
- Flora E Van LeeuwenFLFlora E Van Leeuwen
- Laura J Van 'T VeerLVLaura J Van 'T Veer
Open Access
- 11 April 2007
- journal article
- Published by Springer Nature in Breast Cancer Research
- Vol. 9 (2) , R26
Abstract
Introduction: Radiation exposure at a young age is one of the strongest risk factors for breast cancer. Germline mutations in genes involved in the DNA-damage repair pathway (DDRP) may render women more susceptible to radiation-induced breast cancer. Methods: We evaluated the contribution of germline mutations in the DDRP genes BRCA1, BRCA2, CHEK2 and ATM to the risk of radiation-induced contralateral breast cancer (CBC). The germline mutation frequency was assessed, in a case-only study, in women who developed a CBC after they had a first breast cancer diagnosed before the age of 50 years, and who were (n = 169) or were not (n = 78) treated with radiotherapy for their first breast tumour. Results: We identified 27 BRCA1, 5 BRCA2, 15 CHEK2 and 4 truncating ATM germline mutation carriers among all CBC patients tested (21%). The mutation frequency was 24.3% among CBC patients with a history of radiotherapy, and 12.8% among patients not irradiated for the first breast tumour (odds ratio 2.18 (95% confidence interval 1.03 to 4.62); p = 0.043). The association between DDRP germline mutation carriers and risk of radiation-induced CBC seemed to be strongest in women who developed their second primary breast tumour at least 5 years after radiotherapy. Those patients had an odds ratio of 2.51 (95% confidence interval 1.03 to 6.10; p = 0.049) of developing radiation-induced breast cancer, in comparison with non-carriers. Conclusion: This study shows that carriers of germline mutations in a DDRP gene have an increased risk of developing (contralateral) breast cancer after radiotherapy; that is, over and above the risk associated with their carrier status. The increased risk indicates that knowledge of germline status of these DDRP genes at the time of breast cancer diagnosis may have important implications for the choice of treatment.Keywords
This publication has 41 references indexed in Scilit:
- The spectrum of ATM missense variants and their contribution to contralateral breast cancerBreast Cancer Research and Treatment, 2007
- Breast Cancer Survival and Tumor Characteristics in Premenopausal Women Carrying the CHEK2*1100delC Germline MutationJournal of Clinical Oncology, 2007
- Effect of Chest X-Rays on the Risk of Breast Cancer Among BRCA1/2 Mutation Carriers in the International BRCA1/2 Carrier Cohort Study: A Report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators’ GroupJournal of Clinical Oncology, 2006
- The CHEK2*1100delC Allelic Variant and Risk of Breast Cancer: Screening Results from the Breast Cancer Family RegistryCancer Epidemiology, Biomarkers & Prevention, 2006
- BRCA1 and BRCA2: 1994 and beyondNature Reviews Cancer, 2004
- CHEK2*1100delC and Susceptibility to Breast Cancer: A Collaborative Analysis Involving 10,860 Breast Cancer Cases and 9,065 Controls from 10 StudiesThe American Journal of Human Genetics, 2004
- Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 StudiesThe American Journal of Human Genetics, 2003
- A CHEK2 Genetic Variant Contributing to a Substantial Fraction of Familial Breast CancerThe American Journal of Human Genetics, 2002
- Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutationsNature Genetics, 2002
- Modifiers of risk of hereditary breast and ovarian cancerNature Reviews Cancer, 2002